News

At SOHO 2025, Lorenzo Falchi, MD, highlighted the critical role of nurses in monitoring and educating patients on toxicities from novel lymphoma therapies.

Michelle Kirschner, MSN, RN, ACNP, APRN-BC, discusses how precision supportive care tailors interventions to patient needs.

Benjamin Besse, MD, PhD, shares AE management strategies with amivantamab/lazertinib in EGFR-positive NSCLC following CHRYSALIS-2 results.

Ghayas C. Issa, MD, MS, discusses key adverse events of menin inhibitors in NPM1-mutated and KMT2Ar AML.

Expert Kelsey Martin shares nursing insights on balancing glucose control and GI side effects when caring for patients on PI3K and AKT inhibitors.

Lisa Hwa Christenson, DNP, CNP, FAPO, shares best practices for monitoring CRS and ICANS with BCMA bispecific antibodies in community oncology.

Karolina Faysman, NP, explains how step-up dosing is used to reduce CRS and ICANS with bispecific antibodies in multiple myeloma.

The role of nurses and APPs is crucial to ensuring patients with cancer can receive newer therapies, shares David A. Braun, MD, PhD.

Nurse practitioner Beth Faiman shares strategies to reduce infection risk in patients receiving bispecific antibodies for multiple myeloma.

Catering supportive care to the individual being treated helps better meet the needs of each patient, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

Lisa Hwa Christenson, APRN, DNP, CNP, FAPO, outlines best practices for safely transitioning patients with multiple myeloma on bispecific antibodies to community care.

Kelsey Martin, APRN, AG-ACNP-BC, AOCNP, discusses current ADCs in breast, bladder, and lung cancer and highlights promising agents in development.

Melissa Rikal, MSN, FNP-BC, AOCNP, shares strategies to help nurses improve adherence and patient education for oral oncolytic therapies.

Nurse practitioner Beth Faiman outlines nursing strategies to monitor, assess, and manage toxicities associated with talquetamab in multiple myeloma.

Melissa Rikal, MSN, FNP-BC, AOCNP, explained that adverse effects are common among the available antibody-drug conjugates in breast cancer.

David A. Braun, MD, PhD, explained that personalized cancer vaccines can be associated with toxicities typical of both vaccines and immunotherapies.

Michelle Kirschner, MSN, RN, ACNP, APRN-BC, explains how educating patients about the Breast Cancer Index can support informed endocrine therapy decisions.

Treatment decisions for older adults after CDK4/6 inhibitors should be tailored, explained Courtney Moore, APRN, FNP-C, OCN.

Experts outline AE risks—including ICANS, CRS, HLH—as T-cell engager use expands, highlighting the crucial role of nurses and APPs.

Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says Stephanie Mompoint, APRN.

Ronald Bleday, MD, explained that a model to reduce opioid use in patients after colorectal surgery relies on nurses familiar with the relevant surgeries.

For patients with HR-positive breast cancer, adverse effects vary by CDK4/6 inhibitor, says Courtney Moore, APRN, FNP-C, OCN.

Kimberly Podsada, BSN, RN, MSN, NP-C, CNS, explained that understanding a patient’s emotional needs can help educate them on treatment adherence.

Survivorship expert Michelle Kirschner, MSN, RN, ACNP, APRN-BC, says that “doable changes” can enhance the lives of patients surviving cancer.

Experienced oncology nurses and APPs can help nurses newer to the field understand who is more at risk of opioid addiction, says expert Ronald Bleday, MD.

Hope S. Rugo, MD, FASCO, emphasized the importance of educating patients about proactive rash and diarrhea management while taking PI3K/AKT inhibitors.

Establishing a routine early in treatment helps proactively manage adverse effects associated with CDK4/6 inhibitors, says Kimberly Podsada, BSN, RN, MSN, NP-C, CNS.

Paolo Tarantino, MD, PhD, explains that the chemotherapy-related toxicities from an ADC are more likely to limit dosage for patients with cancer.

While CIML natural killer immunotherapy can result in infection-like reactions, required prior chemo may cause infections, shared Wenxin (Vincent) Xu, MD.

Patients receiving subcutaneous daratumumab have less chair time and premedication than those receiving IV formulation, says Heather Wenberg, BSN, RN, OCN.